Literature DB >> 24368527

Prognostic relevance of (18)F-FDG PET/CT in carcinoma of unknown primary.

Niklas Breuer1, Florian F Behrendt, Alexander Heinzel, Felix M Mottaghy, Moritz Palmowski, Frederik A Verburg.   

Abstract

OBJECTIVES: The aim of this study was to assess whether F-FDG PET combined with x-ray CT (F-FDG PET/CT) findings have a prognostic impact in patients with carcinoma of unknown primary (CUP). PATIENTS AND METHODS: Seventy patients with CUP who were referred for F-FDG PET/CT were included. F-FDG PET/CT results were checked against available histologic diagnosis and follow-up data. For each patient, the SUVmax of the lesion with maximum uptake was measured.
RESULTS: In 26% of the patients, a primary tumor was identified. The follow-up period after F-FDG PET/CT scan ranged between 3 and 45 months. Kaplan-Meier analysis revealed 1-year survival rates of 92% in the group without evidence of malignancy on F-FDG PET/CT, 78% in the group with locoregional disease, and 34% in the group with extensive disease on F-FDG PET/CT. Three-year survival rates in these groups were 73%, 71%, and 23%, respectively (P = 0.001). There was no significant survival difference between patients with regionally confined disease without identification of the primary tumor and those in whom the primary tumor was identified on F-FDG PET/CT (P = 0.25). This was also the case for patients with extensive disease (P = 0.26). The SUVmax of the lesion with maximum uptake was not significantly related to survival (P = 0.56).
CONCLUSIONS: F-FDG PET/CT is a helpful tool for the identification of the primary tumor in patients with CUP; it is also able to provide an accurate assessment of prognosis based on the extent of the disease without the need for identification of the primary tumor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24368527     DOI: 10.1097/RLU.0000000000000304

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.

Authors:  Christian Philipp Reinert; Julia Sekler; Christian la Fougère; Christina Pfannenberg; Sergios Gatidis
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

2.  PET-CT in the sub-arctic region of Norway 2010-2013. At the edge of what is possible?

Authors:  Jan Norum; Ursula Søndergaard; Erik Traasdahl; Carsten Nieder; Geir Tollåli; Gry Andersen; Rune Sundset
Journal:  BMC Med Imaging       Date:  2015-08-28       Impact factor: 1.930

3.  A Unique Case of Diffuse Metastatic Neuroendocrine Cancer with Subcutaneous Nodules on (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computer Assisted Tomography.

Authors:  Mickaila J Johnston; Archana Sachedina; James E McDonald
Journal:  World J Nucl Med       Date:  2015 May-Aug

4.  Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary.

Authors:  Xiaozhou Yu; Xiaofeng Li; Xiuyu Song; Dong Dai; Lei Zhu; Yanjia Zhu; Jian Wang; Huiqin Zhao; Wengui Xu
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

Review 5.  18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis.

Authors:  Synne Alexandra Burglin; Søren Hess; Poul Flemming Høilund-Carlsen; Oke Gerke
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zehra Pınar Koç; Pelin Özcan Kara; Ahmet Dağtekin
Journal:  CNS Oncol       Date:  2018-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.